Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

Journal of Infectious Diseases

Volumn 158, Issue 4, 1988, Pages 831-847

  Vogelman, B ^a   Gudmundsson, S ^a   Leggett, J ^a   Turnidge, J ^a   Ebert, S ^a   Craig, W A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; PENICILLINASE; TICARCILLIN; TOBRAMYCIN;

ANIMAL EXPERIMENT; DRUG BLOOD LEVEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMAL; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CEFAZOLIN; ERYTHROMYCIN; ESCHERICHIA COLI; FEMALE; GENTAMICINS; MICE; MICE, INBRED ICR; PENICILLINS; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; TICARCILLIN; TOBRAMYCIN;

EID: 0023697158     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/158.4.831     Document Type: Article

References (60)

1. Kunin CM. Dosage schedules of antimicrobial agents: A historical review. Rev Infect Dis 1981;3:4-11.
2. Jawetz E. Dynamics of the action of penicillin in experimental animals. Observations on mice. Arch Intern Med 1946; 77:1-15.
3. Schmidt LH, Walley A, Larson RD. The influence of the dosing regimen on the therapeutic activity of penicillin G. J Pharmacol Exp Ther 1949;96:258-68.
4. Schmidt LH, Walley A. The influence of the dosage regimen on the therapeutic effectiveness of penicillin G in experimental lobar pneumonia. J Pharmacol Exp Ther 1951;I03: 479-88.
5. Eagle H, Magnuson HJ, Fleischman R. The effect of the method of administration on the therapeutic efficacy of sodium penicillin in experimental syphilis. Bulletin of the Johns Hopkins Hospital 1946;79:168-89.
6. Eagle H, Fleischman R, Levy M. “Continuous” vs. “discontinuous” therapy with penicillin. The effect of the interval between injections on therapeutic efficacy. N Engl J Med 1953;248:481-8.
7. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(Suppl A):37-46.
8. Gudmundsson S, Vogelman B, Craig WA. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986;18(Suppl E):67-73.
9. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, ed. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins, 1986:515-36.
10. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988;157:287-98.
11. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
12. Gerber AU, Craig WA, Brugger H-P, Feller C, Vastola AP, Brandei J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983;147:910-7.
13. Bakker-Woudenberg IAJM, van den Berg JC, Fontijne P, Michel MF. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol 1984;34:131-5.
14. Roosendaal R, Bakker-Woudenberg IAJM, van den Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985;1562:373-8.
15. Roosendaal R, Bakker-Woudenberg IAJM, van den Berghe-van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-8.
16. Ingerman MJ, Pitsakis PG, Rosenberg AF, Levison ME. The importance of pharmocodynamics in determining the dosing interval in therapy for experimental Pseudomonas endocarditis in the rat. J Infect Dis 1986;163:707-14.
17. Thauvin C, Eliopoulos GM, Willey S, Wennersten C, Moeller-ing RC Jr. Continuous-infusion ampicillin therapy of en-terococcal endocarditis in rats. Antimicrob Agents Chemother 1987;31:139-43.
18. Mordenti JJ, Quintiliani R, Nightingale CH. Combination antibiotic therapy: Comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 1985;15(Suppl A):313-21.
19. Gengo FM, Mannion TW, Nightingale CH, Schentag JJ. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother 1984;14:619-31.
20. Täuber MG, Zak O, Scheid WM, Hengstier B, Sande MA. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis 1984;149:575-83.
21. Kapusnik JE, Gordin F, Scott K, Hackbarth C, Sande MA. Efficacy of once daily versus conventional aminoglycoside therapy for experimental Pseudomonas pneumonia [abstract]. Clin Res 1985;33:57a.
22. Kapusnik J, Hackbarth C, Chambers H, Scott K, Carpenter T, Sande M. Efficacy of once daily verus intermittent dosing of tobramycin in neutropenic and normal, sedated guinea pigs with experimental pseudomonas pneumonia [abstract 548]. In: Programs and abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1985.
23. Kapusnik JE, Sande MA. Novel approaches for the use of aminoglycosides: The value of experimental models. J Antimicrob Chemother 1986;17(Suppl 1):7-10.
24. Powell SH, Thompson WL, Luthe MA, Stern RC, Gross-niklaus DA, Bloxham DD, Groden DL, Jacobs MR, Di-Scenna AO, Cash HA, Klinger JD. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
25. Queiroz MLS, Bathirunathan N, Mawer GE. Influence of dosage interval on the therapeutic response to gentamicin in mice infected with Klebsiella pneumoniae. Chemotherapy 1987;33:68-76.
26. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol 1983;2:554-8.
27. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
28. Feld R, Valdivieso M, Bodey GP, Rodriguez V. A comparative trial of sisomicin therapy by intermittent versus continuous infusion. Am J Med Sei 1977;274:179-88.
29. Feld R, Rachlis A, Tuffnell PG, Duncan I, Moran L, Pinfold P, DeBoer G. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med 1984;144:1005-10.
30. Nordstrom L, Cronberg S, Ringberg H, Tjernström Ö, Walder M. Prospective, comparative, randomized clinical study of aminoglycosides given once a day versus three times a day in severe infections. In: Ishigami J, ed. Recent advances in chemotherapy. Antimicrobial section 3. Proceedings of the 14th International Congress of Chemotherapy, Kyoto. Tokyo: University of Tokyo Press, 1985:2653-4.
31. Pennington JE, Stone RM. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis 1979;140:881-9.
32. Pennington JE, Johnson CE, Platt R. Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs. J Infect Dis 1982;146:567.
33. Pennington JE, Johnson CE. Comparative activities of N-for-mimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 1982;22:406-8.
34. Johnson M, Miniter P, Andriole VT. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental pseudomonas sepsis. J Infect Dis 1987;155:783-8.
35. Norden CW, Shaffer MA. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 1982;21:62-5.
36. Klastersky J, Daneau D, Swings G, Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis 1974;129:187-93.
37. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984;76: 429-35.
38. Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:477-81.
39. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.
40. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gramnegative pneumonia. Am J Med 1984;77:657-62.
41. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
42. Bodey GP, Rodriguez V, Valdivieso M, Feld R. Amikacin for treatment of infections in patients with malignant diseases. J Infect Dis 1976;134(Suppl)L: S421-7.
43. Keating MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides-comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979;59:159-70.
44. Standiford H, Joshi H, Wade J, deJongh C, Johnson D, Drusano G, Schimpff S. Correlation of serum bactericidal activity and response in profoundly granulocytopenic cancer patients with gram-negative bacteremia [abstract 159). In: Program and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1984.
45. Edberg SC, Sabath LD. Determination of antibiotic levels in body fluids: Techniques and significance. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: Williams and Wilkins, 1980:206-64.
46. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1975.
47. Ryan DM, Cars O. Antibiotic assays in muscle: Are conventional tissue levels misleading as indicator of the antibacterial activity? Scand J Infect Dis 1980;12:307-9.
48. Eagle H, Fleischman R, Musselman AD. The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum. J Bacteriol 1950; 59:625-43.
49. Frimodt-M0ller N, Bentzon MW, Thomsen VF. Experimental infection with Streptococcus pneumoniae in mice: Correlation of in vitro activity and pharmacokinetic parameters in vivo effect for 14 cephalosporins. J Infect Dis 1986;154: 511-7.
50. Nishi T, Tsuchiya K. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: Chemotherapy with kanamycin. Antimicrob Agents Chemother 1980;17: 494-505.
51. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986;5:319-24.
52. Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med 1984;77(Suppl 6A):43-50.
53. Gonda I. On predictions of free antibiotic (cefazolin) concentrations in extravascular fluids from ‘logarithmic mean serum concentrations.’ J Antimicrob Chemother 1982;9: 53-6.
54. Mordenti J. Interspecies pharmacokinetic modeling and dose selection for experimental animal infections. In: Ishigami J, ed. Recent advances in chemotherapy. Antimicrobial section 3. Proceedings of the 14th International Congress of Chemotherapy, Kyoto. Tokyo: University of Tokyo Press, 1985:633-4.
55. Johnson DE, Thompson B, Calia FM. Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrob Agents Chemother 1985;28:735-9.
56. Trautmann M, Brückner Ö, Marre R, Hahn H. Comparative efficacy of different β-lactam antibiotics and gentamicin in Klebsiella pneumoniae septicemia in neutropenic mice. J Antimicrob Chemother 1986;18:387-91.
57. Smith CR, Ambinder R, Lipsky JJ, Petty BG, Israel E, Levitt R, Mellits ED, Rocco L, Longstreth J, Lietman PS. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Ann Intern Med 1984;101:469-77.
58. De Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;80(Suppl 6B): 115-8.
59. Craig WA, Vogelman B. Changing patterns of hospital infections: Implications for therapy. Changing concepts and new applications of antibiotic pharmacokinetics. Am J Med 1984;77(Suppl 1B):24-48.
60. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H, the European Organization for Research on Treatment of Cancer Antimicrobial Therapy Project Group. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986;29:263-70.